Duopharma, govt execute agreement for insulin worth RM375.17mil via direct negotiation

KUALA LUMPUR: Duopharma Biotech Bhd and the government have executed the agreement to procure insulin medicines via direct negotiation for RM375.17 million, a Bursa Malaysia filing said.

The company said wholly-owned subsidiary Duopharma Marketing Sdn Bhd (DMktg) will supply and deliver the products to the Health Ministry while Biocon Sdn Bhd, the manufacturer, will pack and label the products under the agreement.

Biocon's human insulin formulation will be supplied to all MoH hospitals, district health offices and health clinics.

The three-year agreement is from Apr 29, 2022 to Apr 28, 2025. It may be extended based on terms and conditions to be agreed on by the parties.

Malaysia has an estimated 3.9 million diabetics, with 420,000 using human insulin in the government hospitals and clinics.

DMktg and Biocon hope to improve diabetes management in the country by providing high quality and cost-effective biosimilar insulins. - Bernama

Article type: free
User access status:
Subscribe now to our Premium Plan for an ad-free and unlimited reading experience!

DMktg , Biocon , insulin , MOH , Bursa Malaysia 


Next In Business News

US and UK should be welcoming talent, not driving it away
Short Position: Ringgit rebound, PETRONAS earnings
KWAP seeks stronger income growth
What’s in fashion
Brexiteers, no one wants your regulatory bonfire
EcoWorld redefines concept behind industrial parks
S’pore chips away at HK’s hedge fund dominance
Ringgit seen strengthening further
Hibiscus gets debt boost
Navigating a ‘perfect positive storm’

Others Also Read